Spyros Papapetropoulos - 27 Aug 2025 Form 4 Insider Report for Neuphoria Therapeutics Inc. (NEUP)

Reporting relationship: President and CEO, Director
Issuer ticker: NEUP
Reported as of: 27 Aug 2025
Net transaction value: +$285,803
SEC form: 4
Accepted by SEC: 02 Sep 2025, 07:02:44 UTC
Prior SEC filing: 05 Jun 2025
Source filing: View source filing
Reporting owner signature: /s/ Spyros Papapetropoulos

Key filing fact

Spyros Papapetropoulos filed Form 4 for Neuphoria Therapeutics Inc. (NEUP) on 02 Sep 2025.

Key facts

This page summarizes Spyros Papapetropoulos's Form 4 filing for Neuphoria Therapeutics Inc. (NEUP).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 02 Sep 2025, 07:02.

Change

Previous filing in this sequence was filed on 05 Jun 2025.
Current net transaction value: +$285,803.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001832694 Primary reporting owner

Papapetropoulos Spyros

Relationship: President and CEO, Director
Address: 100 SUMMIT DRIVE, BURLINGTON
Signature: /s/ Spyros Papapetropoulos
Signature date: 01 Sep 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

NEUP transaction Derivative

Employee Stock Option (Right-to- Buy)

Award

Transaction value: $285,803
Shares: +34,559
Change %: +87%
Price: $8.27
Shares after: 74,088
Date: 27 Aug 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 34,559
Exercise price: $8.27
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Subject to the Reporting Person's continuing service with the Company, the options shall vest on a monthly basis over a four-year period at the rate of 2.0833% of the shares of Common Stock on the last day of each month following August 1, 2025 until the options are fully vested.